ライフサイエンスコーパス: relapsing-remitting multiple sclerosis

1 rol groups (healthy donors and patients with relapsing-remitting multiple sclerosis).

2 condary progressive than in those who remain relapsing remitting multiple sclerosis.

3 the CSF of progressive patients compared to relapsing remitting multiple sclerosis.

4 ects of IFN-beta therapy in the treatment of relapsing remitting multiple sclerosis.

5 ing lesions on magnetic resonance imaging in relapsing remitting multiple sclerosis.

6 trial of estriol is warranted in women with relapsing remitting multiple sclerosis.

7 t approved oral therapy for the treatment of relapsing remitting multiple sclerosis.

8 lications for the diagnosis and treatment of relapsing remitting multiple sclerosis.

9 ins the most widely prescribed treatment for relapsing remitting multiple sclerosis.

10 ormalities between secondary progressive and relapsing remitting multiple sclerosis.

11 Fingolimod is an effective treatment for relapsing-remitting multiple sclerosis.

12 ort further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis.

13 mmunomodulator approved for the treatment of relapsing-remitting multiple sclerosis.

14 ephalomyelitis (EAE) that mirror chronic and relapsing-remitting multiple sclerosis.

15 more efficacious than either agent alone in relapsing-remitting multiple sclerosis.

16 response to interferon beta in patients with relapsing-remitting multiple sclerosis.

17 od reduces disease activity in patients with relapsing-remitting multiple sclerosis.

18 rolled phase 3 study involving patients with relapsing-remitting multiple sclerosis.

19 ebo-controlled study involving patients with relapsing-remitting multiple sclerosis.

20 y, as compared with placebo in patients with relapsing-remitting multiple sclerosis.

21 s aged 18-50 years with previously untreated relapsing-remitting multiple sclerosis.

22 trial of previously untreated patients with relapsing-remitting multiple sclerosis.

23 tivity in previously untreated patients with relapsing-remitting multiple sclerosis.

24 reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis.

25 in a Phase I/IIa clinical trial in new-onset relapsing-remitting multiple sclerosis.

26 -course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

27 s highly effective in the treatment of early relapsing-remitting multiple sclerosis.

28 and Crohn's disease but a negative result in relapsing-remitting multiple sclerosis.

29 B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.

30 encephalomyelitis (EAE), an animal model of relapsing-remitting multiple sclerosis.

31 ing very late antigen-4 for the treatment of relapsing-remitting multiple sclerosis.

32 ve Th cell clone derived from a patient with relapsing-remitting multiple sclerosis.

33 l simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis.

34 yelitis and reduces the relapse frequency in relapsing-remitting multiple sclerosis.

35 ne may provide a novel therapeutic agent for relapsing-remitting multiple sclerosis.

36 the central nervous system of patients with relapsing-remitting multiple sclerosis.

37 unction rather than loss in clinically early relapsing-remitting multiple sclerosis.

38 esion probability maps from 19 patients with relapsing-remitting multiple sclerosis.

39 une diseases and is a first-line therapy for relapsing-remitting multiple sclerosis.

40 )-infiltrating lymphocytes are a hallmark of relapsing-remitting multiple sclerosis.

41 in progressive disease and more localized in relapsing-remitting multiple sclerosis.

42 steps are illustrated using an example from relapsing-remitting multiple sclerosis.

43 red with once every 4 weeks in patients with relapsing-remitting multiple sclerosis.

44 ographically diverse cohort of patients with relapsing-remitting multiple sclerosis.

45 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.

46 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

47 rug Administration approved for treatment of relapsing-remitting multiple sclerosis.

48 negative prognostic factor in patients with relapsing-remitting multiple sclerosis.

49 rferon beta-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.

50 d for the treatment of people suffering from relapsing-remitting multiple sclerosis.

51 lockade on Treg homeostasis in patients with relapsing-remitting multiple sclerosis.

52 erapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis.

53 ing agent in the management of patients with relapsing-remitting multiple sclerosis.

54 al effects on relapse rates in patients with relapsing-remitting multiple sclerosis.

55 the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis.

56 al and MRI disease activity in patients with relapsing-remitting multiple sclerosis.

57 and efficacy of amiselimod in patients with relapsing- remitting multiple sclerosis.

58 ation due to adverse events in patients with relapsing-remitting multiple sclerosis?

59 Participants were patients with relapsing-remitting multiple sclerosis 18 to 55 years ol

60 -progressive (49.3 +/- 8.0 mM) compared with relapsing-remitting multiple sclerosis (43.0 +/- 8.5 mM,

61 trial of annual alemtuzumab for treatment of relapsing-remitting multiple sclerosis, 6 of 216 patient

62 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro

63 In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, p

64 l trials (Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety

65 Patients with relapsing-remitting multiple sclerosis (age 18-65 years,

66 atients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab coul

67 We studied 21 patients with relapsing-remitting multiple sclerosis and 16 age- and s

68 ross-sectional study of 41 patients, 21 with relapsing-remitting multiple sclerosis and 20 with secon

69 000 ms, nominal voxel volume 2.3 ml) from 27 relapsing-remitting multiple sclerosis and 29 normal con

70 al, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one

71 PIRA begins in relapsing-remitting multiple sclerosis and becomes the d

72 uded participants were aged 18-60 years with relapsing-remitting multiple sclerosis and had been trea

73 resonance imaging at 3 T in 17 patients with relapsing-remitting multiple sclerosis and in 13 normal

74 expression was increased in individuals with relapsing-remitting multiple sclerosis and in mice with

75 and white matter atrophy in clinically early relapsing-remitting multiple sclerosis and its relations

76 Among patients with active relapsing-remitting multiple sclerosis and moderate disa

77 During the clinical relapse of both, relapsing-remitting multiple sclerosis and neuromyelitis

78 58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary pro

79 ean age 54.3 +/- 10.5 years, 58% female, 63% relapsing-remitting multiple sclerosis) and 60 healthy c

80 Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had complete

81 n of interferon-beta's therapeutic effect in relapsing-remitting multiple sclerosis, and has implicat

82 n oral therapy approved for the treatment of relapsing-remitting multiple sclerosis, and it is known

83 fluid samples of patients with encephalitis, relapsing-remitting multiple sclerosis, and other neurol

84 ears old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive

85 atents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, cre

86 their effects on disability in patients with relapsing-remitting multiple sclerosis are maintained an

87 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of

88 In the treatment of relapsing-remitting multiple sclerosis, autologous hemat

89 In patients with relapsing-remitting multiple sclerosis, BG-12 (at both d

90 In patients with relapsing-remitting multiple sclerosis, both BG-12 regim

91 ging has been examined in small cohorts with relapsing-remitting multiple sclerosis, but has not been

92 every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associate

93 than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy

94 and North America reduce the relapse rate in relapsing/remitting multiple sclerosis by about 30%.

95 Cognitive dysfunction in people with relapsing-remitting multiple sclerosis can improve with

96 rimary and secondary-progressive compared to relapsing-remitting multiple sclerosis (coefficients = -

97 ratio values in the outer cord were lower in relapsing-remitting multiple sclerosis compared with cli

98 onse to CRH was greater in the patients with relapsing-remitting multiple sclerosis compared with the

99 rs was 0.80 cm3/year in those who retained a relapsing remitting multiple sclerosis course, and 2.89

100 Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP s

101 at the rate and extent of axonal loss during relapsing-remitting multiple sclerosis determines when a

102 A 46-year-old woman with relapsing-remitting multiple sclerosis died from progres

103 DMTs by comparing a cohort of patients with relapsing-remitting multiple sclerosis enrolled in the U

104 atients with clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disabil

105 ed cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing rela

106 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one

107 trial, patients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres i

108 In 140 eyes from 70 patients having relapsing-remitting multiple sclerosis from January 2011

109 d data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase a

110 2a trial (CCMR One) recruited patients with relapsing-remitting multiple sclerosis from two centres

111 As treatment for relapsing-remitting multiple sclerosis, glatiramer aceta

112 progressive multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these

113 In the clinically isolated syndrome and relapsing-remitting multiple sclerosis groups, outer cor

114 3 years disease duration), 18 subjects with relapsing-remitting multiple sclerosis (>/= 4 years dise

115 y neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the i

116 Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an o

117 terferons and glatiramer in the treatment of relapsing-remitting multiple sclerosis has been advanced

118 tive disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been license

119 at have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no

120 A) is widely prescribed for the treatment of relapsing-remitting multiple sclerosis, however, the mec

121 s use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit

122 as proven to be highly efficacious in active relapsing-remitting multiple sclerosis; however, the hig

123 igher in secondary-progressive compared with relapsing-remitting multiple sclerosis in cortical grey

124 ,E,A,K)n] is widely used in the treatment of relapsing/remitting multiple sclerosis in which it reduc

125 , which is currently used as a treatment for relapsing, remitting multiple sclerosis, is a potent imm

126 IFN-beta, an effective therapy against relapsing-remitting multiple sclerosis, is naturally sec

127 tissue sodium concentration in patients with relapsing-remitting multiple sclerosis might reflect cha

128 Second, PBL obtained from patients with relapsing/remitting multiple sclerosis mount a prolifera

129 ly measured ex vivo in subjects with typical relapsing remitting multiple sclerosis (MS).

130 FTY720 is a treatment for relapsing remitting multiple sclerosis (MS).

131 e cerebrospinal fluid of patients with early relapsing-remitting multiple sclerosis (MS) and in activ

132 n the brains and spinal cords of people with relapsing-remitting multiple sclerosis (MS) and progress

133 des of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a

134 Available treatment options for relapsing-remitting multiple sclerosis (MS) have expande

135 immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the Unite

136 The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influence

137 pinal fluid (CSF) samples from patients with relapsing-remitting multiple sclerosis (MS) obtained wit

138 Unexpectedly, progressive and relapsing-remitting multiple sclerosis (MS) patients hav

139 on medications and disease progression among relapsing-remitting multiple sclerosis (MS) patients in

140 f anti-OSP Abs in the cerebrospinal fluid of relapsing-remitting multiple sclerosis (MS) patients, bu

141 reduces the frequency of relapses by 30% in relapsing-remitting multiple sclerosis (MS) patients.

142 Patients who develop relapsing-remitting multiple sclerosis (MS) present with

143 No current therapy for relapsing-remitting multiple sclerosis (MS) results in s

144 c stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not

145 uperior efficacy over interferon beta-1a for relapsing-remitting multiple sclerosis (MS), and is curr

146 iety of human autoimmune diseases, including relapsing-remitting multiple sclerosis (MS), in which in

147 n placebo-controlled phase II/III studies of relapsing-remitting multiple sclerosis (MS).

148 r the past 15 years as a primary therapy for relapsing-remitting multiple sclerosis (MS).

149 ted efficacy in reducing disease activity in relapsing-remitting multiple sclerosis (MS).

150 bif) have shown efficacy in the treatment of relapsing-remitting multiple sclerosis (MS).

151 to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).

152 g by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS).

153 utor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS).

154 ical and MRI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

155 acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).

156 a control cohort of neurologic autoimmunity (relapsing-remitting multiple sclerosis [MS] n = 110, HD

157 ts with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progr

158 response is a crucial step for patients with relapsing-remitting multiple sclerosis on disease-modify

159 center: nine healthy participants, two with relapsing-remitting multiple sclerosis, one with persist

160 PBMCs isolated from healthy humans and relapsing remitting multiple sclerosis patients and sple

161 In a pilot trial, oral estriol treatment of relapsing remitting multiple sclerosis patients caused s

162 We previously reported that relapsing remitting multiple sclerosis patients treated

163 e only detected in dimethyl fumarate-treated relapsing remitting multiple sclerosis patients.

164 Analysis of pEVs from relapsing-remitting multiple sclerosis patients also ide

165 nd extra-cellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 h

166 xonal analysis could define axonal damage in relapsing-remitting multiple sclerosis patients earlier

167 The study included relapsing-remitting multiple sclerosis patients from the

168 III multi-center trial of oral myelin in 515 relapsing-remitting multiple sclerosis patients is in pr

169 gn, peripheral blood was obtained from eight relapsing-remitting multiple sclerosis patients just bef

170 nd 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using mu

171 cohort, modeled data were obtained from 621 relapsing-remitting multiple sclerosis patients, who wer

172 ved with brain magnetic resonance imaging in relapsing-remitting multiple sclerosis patients.

173 tory cytokines IL-27 and IL-10 in PBMCs from relapsing-remitting multiple sclerosis patients.

174 The patient cohort was composed of 159 relapsing-remitting multiple sclerosis patients.

175 m safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients.

176 312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence

177 pressive function is impaired in people with relapsing-remitting multiple sclerosis (pwRR-MS).

178 disagreement among devices in patients with relapsing-remitting multiple sclerosis regarding the ON

179 inical trial of simvastatin in patients with relapsing remitting multiple sclerosis (RR MS), which de

180 is a first-line immunomodulatory therapy for relapsing-remitting multiple sclerosis (RR MS).

181 an CSF, and was compared among subjects with relapsing-remitting multiple sclerosis (RR-MS; n = 52),

182 ntegrity of processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and other

183 Foxp3(+) T cells in untreated subjects with relapsing remitting multiple sclerosis (RRMS) as compare

184 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe

185 ured serum metabolites from 35 patients with relapsing-remitting multiple sclerosis (RRMS) and 14 hea

186 ger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-a

187 ed the separation of diagnostic criteria for relapsing-remitting multiple sclerosis (RRMS) and primar

188 and clinical findings between patients with relapsing-remitting multiple sclerosis (RRMS) and second

189 -3(+) CD4 and CD8 T cells from subjects with relapsing-remitting multiple sclerosis (RRMS) and type 1

190 cting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lackin

191 Disease-modifying drugs (DMDs) for relapsing-remitting multiple sclerosis (RRMS) are only p

192 TCR stimulation is impaired in subjects with relapsing-remitting multiple sclerosis (RRMS) because of

193 tokine polarization profile in patients with relapsing-remitting multiple sclerosis (RRMS) by high-di

194 Focal inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) diminishes

195 Patients with relapsing-remitting multiple sclerosis (RRMS) have an in

196 umab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe,

197 The mechanism of IFN-beta therapy in relapsing-remitting multiple sclerosis (RRMS) is not wel

198 Early treatment choice in relapsing-remitting multiple sclerosis (RRMS) is prognos

199 The main goal of treatment in relapsing-remitting multiple sclerosis (RRMS) is to redu

200 B cell depletion in patients with relapsing-remitting multiple sclerosis (RRMS) markedly p

201 mbulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or seconda

202 of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an ex

203 e total circulating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients a

204 e previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients e

205 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients w

206 (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients.

207 Even within the relapsing-remitting multiple sclerosis (RRMS) population

208 osis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed tha

209 stekinumab, were used to treat patients with relapsing-remitting multiple sclerosis (RRMS) to assess

210 The transition from relapsing-remitting multiple sclerosis (RRMS) to seconda

211 Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary marke

212 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzum

213 atiramer acetate are commonly prescribed for relapsing-remitting multiple sclerosis (RRMS), but no pu

214 le SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laqu

215 a Swedish nationwide observational study in relapsing-remitting multiple sclerosis (RRMS), to identi

216 a Swedish nationwide observational study in relapsing-remitting multiple sclerosis (RRMS), to identi

217 In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORM

218 long-lasting disease activity suppression in relapsing-remitting multiple sclerosis (RRMS).

219 a is the treatment most often prescribed for relapsing-remitting multiple sclerosis (RRMS).

220 ental autoimmune encephalomyelitis (EAE) and relapsing-remitting multiple sclerosis (RRMS).

221 frequency of exacerbations in patients with relapsing-remitting multiple sclerosis (RRMS).

222 utor to long-term disability accumulation in relapsing-remitting multiple sclerosis (RRMS).

223 two cohorts of patients with mixed NMOSD and relapsing-remitting multiple sclerosis (RRMS).

224 s normal aging, or can be distinguished from relapsing-remitting multiple sclerosis (RRMS).

225 cetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS).

226 factors with long-term clinical outcomes in relapsing-remitting multiple sclerosis (RRMS).

227 odulator, for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

228 ta has been used as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS).

229 ory oral agent approved for the treatment of relapsing-remitting multiple sclerosis (RRMS); however,

230 ion with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study,

231 ion With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and I

232 Subjects with relapsing-remitting multiple sclerosis showed a greater

233 were enrolled in this study, 24 patients had relapsing remitting multiple sclerosis, six had progress

234 a T cell receptor (TCR) from a patient with relapsing-remitting multiple sclerosis that engages its

235 ly characterized by relapses and remissions (relapsing-remitting multiple sclerosis) that over time m

236 oncentric sclerosis and in a subset of early relapsing remitting multiple sclerosis, the initial myel

237 ns is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accu

238 erapies have revolutionized the treatment of relapsing-remitting multiple sclerosis, they are less ef

239 In patients with relapsing-remitting multiple sclerosis, those who worsen

240 s, and more so in secondary progressive than relapsing remitting multiple sclerosis, tissue structura

241 , phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare dacliz

242 The mechanism underlying the progression of relapsing-remitting multiple sclerosis to secondary prog

243 ligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingol

244 olimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to

245 The study included patients with relapsing-remitting multiple sclerosis treated with auto

246 In patients with relapsing-remitting multiple sclerosis, treatment with a

247 Serum IL-21 from 141 individuals with relapsing remitting multiple sclerosis was measured usin

248 d, 48-week trial involving 104 patients with relapsing-remitting multiple sclerosis, we assigned 69 p

249 A total of 1106 patients with relapsing-remitting multiple sclerosis were randomly ass

250 Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly ass

251 d Disability Status Score (EDSS) 0-7.5] with relapsing-remitting multiple sclerosis were selected on

252 autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered

253 ) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonl

254 udy, we randomly assigned 1292 patients with relapsing-remitting multiple sclerosis who had a recent

255 Forty-two patients with relapsing-remitting multiple sclerosis who were treated

256 a woman in her late 30s with a diagnosis of relapsing-remitting multiple sclerosis, who continued to

257 The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequen

258 Treatment of early relapsing-remitting multiple sclerosis with the lymphocy

259 s (21 with secondary progressive and 28 with relapsing-remitting multiple sclerosis) with mixed or hi

260 tified adult patients (aged >=18 years) with relapsing-remitting multiple sclerosis, with at least 6